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INTRODUCTION
In the early 1980s, it was proven that cyclosporin A (CsA) is more
effective than azathioprine (AZA) in preventing acute rejection
of renal allografts [1–3]. However, the chronic use of CsA is asso-
ciated with multiple side effects, e.g. nephrotoxicity and hyper-
tension [2,4,5]. To minimize these side effects, and in an attempt
to preserve benefits on graft survival, administration of CsA for
one year and thereafter, conversion to the less nephrotoxic drugs
AZA [6–10] or mycophenolate mofetil (MMF) [10], would be an
option. To reduce the long-term side effects (cancer) [11] of
immunosuppressive agents, and to improve the quality of life after
transplantation, the AZA, MMF or prednison (Pred) dose can be
tapered [10,12,13], provided this is not accompanied by rejection.
In some patients, it is even possible to discontinue the immuno-
suppression completely [14,15], suggesting that donor-specific
non-responsiveness can occur following transplantation.
In vitro studies have demonstrated that donor-specific hypore-
sponsiveness can be observed in mixed lymphocyte culture
(MLC), cell-mediated lympholysis (CML), and cytotoxic (CTLpf)
and helper (HTLpf) T-lymphocyte precursor frequencies [16–21].
Some studies have described T-cell reactivity before (no immuno-
suppression) and after transplantation (high dose immunosup-
pression) [16,21–24]. To date, only a few studies have measured
T-cell reactivity before (high dose immunosuppression) and after
tapering (low dose immunosuppression) immunosuppression,
although in a small number of patients [17,20,25,26]. All these
results suggested that transplant acceptance might be reflected by
in vitro donor antigen-specific hyporeactivity.
To our knowledge, no controlled study has been performed in
stable renal transplant patients to investigate T-cell reactivity
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SUMMARY
Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either
azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side
effects of long-term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually
tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosup-
pressive treatment results in a rise of donor-specific T-cell reactivity. Before transplantation (no
immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppres-
sion) after transplantation, the T-cell reactivity of peripheral blood mononuclear cells (PBMC) against
donor and third-party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus
toxoid (TET) to test the general immune response. We also measured the frequency of donor and third-
party reactive helper (HTLpf) and cytotoxic (CTLpf) T-lymphocyte precursors in a limiting dilution
assay. Donor-specific responses, calculated by relative responses (RR = donor/third-party reactivity),
were determined. Comparing responses after transplantation during high dose immunosuppression
with responses before transplantation (no immmunosuppression), the donor-specific MLC-RR (P =
0·04), HTLp-RR (P = 0·04) and CTLp-RR (P = 0·09) decreased, while the TET-reactivity did not
change. Comparing the responses during low dose with high dose immunosuppression, no donor-
specific differences were found in the MLC-RR, HTLp-RR and CTLp-RR, although TET-reactivity
increased considerably (P = 0·0005). We observed a reduction in donor-specific T-cell reactivity in stable
patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the
immunosuppressive load had no rebound effect on the donor-specific reactivity, while it allowed recov-
ery of the response to nominal antigens.
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before transplantation, during high dose immunosuppression and
during tapered or low dose immunosuppression. We questioned
what effect the reduction of immunosuppressive treatment could
have on donor-specific responses. Therefore, we studied T-cell
reactivity in 20 stable renal transplant recipients before trans-
plantation (no immunosuppression), one year after trans-
plantation and treatment with CsA and Pred (high dose 
immunosuppression), and two years after transplantation when
the patients were successfully converted and successfully (without
the occurrence of acute rejection) tapered in their treatment with
AZA or MMF and Pred (low dose immunosuppression). Donor-
specific reactivity was measured in MLC and in limiting dilution
assays (LDA) to study HTLpf and CTLpf. The non-HLA-specific
TET-reactivity was used to test the general immune response.
MATERIALS AND METHODS
Patients
Between September 1995 and January 1997, 80 cadaveric kidney
transplantations were performed in Rotterdam. Forty-six patients
with stable graft function 1 year after transplantation, without
acute rejection in the last 6 months, were routinely converted
from CsA (whole blood trough level: ±150 ng/ml) and Pred 
(10 mg/day), to either AZA (2 mg/kg/day) (n = 22) or MMF 
(2 g/day) (n = 24) and Pred (10 mg/day), in a prospective and ran-
domised controlled study [10]. CsA was gradually discontinued
within 1 month after the start of AZA or MMF medication. In
stable patients, the AZA and MMF dose was reduced to 75% at
4 months and to 50% at 8 months after conversion, reaching main-
tenance treatment of 1 mg/kg/day AZA or 1 g/day MMF. Thirty
stable patients were able to complete the whole study period of
2 years (4 months after the last dose reduction). From 20 patients,
PBMC and donor spleen cells were available to study the T-cell
reactivity before renal transplantation (no immunosuppression),
1 year after transplantation (CsA therapy; high dose immuno-
suppression) and 2 years after transplantation (tapered AZA (n
= 10) or MMF (n = 10) treatment; low dose immunosuppression).
The mean number of HLA-A, -B and -DR mismatches on broad
antigens was 1·9 ± 1·3 (s.d.) (range: 0–4) in the AZA group, and
1·8 ± 1·6 (range 0–4) in the MMF group.
Peripheral blood mononuclear cells (PBMC) and spleen 
cell sampling
PBMC samples were isolated as described before [27] and stored
at –140°C until use.
Spleen cells were obtained by mechanical dissociation of
small pieces of spleen derived from the organ donor [27]. Subse-
quently, the cell suspension was filtered through a 40 mm cell
strainer (Falcon, Franklin Lakes, NJ, USA) and washed. There-
after, the cells were centrifuged over a Ficoll-Paque (Amersham
Pharmacia Biotech, Uppsala, Sweden) density gradient, collected,
washed and stored at –140°C.
Mixed lymphocyte culture (MLC) and tetanus toxoid 
(TET) stimulation
For MLC and TET stimulation, 100 ml of a 5¥ 104 PBMC 
suspension in culture medium (RPMI 1640-DM (GI B C O BRL,
Paisley, UK) supplemented with 2 mM L-glutamine (GI B C O ), 
100 IU/ml penicillin (BioWhittaker, Verviers, Belgium), 100 mg/ml
streptomycin (BioWhittaker) and 10% pooled, heat-inactivated
human serum that was tested for adequate cell-growth support in
MLC) were added in triplicate wells in a round-bottomed 96-well
plate (Nunc, Roskilde, Denmark) to 100 ml culture medium con-
taining: (a) 5 ¥ 104 irradiated (45 Gy) spleen cells derived from
the donor; (b) 5 ¥ 104 irradiated (45 Gy) spleen cells derived from
a third-party which did not share HLA antigens with the donor
and patient. For each patient the same third-party cells were used
in all experiments; (c) TET (RIVM, Bilthoven, The Netherlands)
at 7·5 lf/ml final concentration as nominal antigen to test the
general immune response; (d) phytohaemagglutinin M (PHA;
1:100 final dilution; Difco Laboratories, Detroit, MI, USA) to
control the viability of the cells; and (e) culture medium. After 7
days (3 days in the case of the PHA control) of incubation at 37°C
in a humidified atmosphere of 5% CO2 in air, cell proliferation
was measured by incorporation of 3H-thymidine (0·5 mCi/well:
Amersham Pharmacia Biotech) which was added during the last
8 h of culture. The cells were harvested as described before [27].
The mean counts per minute (cpm) were determined and the
stimulation index (SI) was calculated by the ratio of the cpm
obtained in the presence of antigen to the cpm in the absence of
antigen.
Limiting dilution assay (LDA)
Limiting dilution cultures were set up in 96-well U-bottomed
tissue plates (Nunc). Twenty-four replicates of graded number
PBMC responders were titrated in seven-step double dilutions,
starting from 5 ¥ 104 to 781 PBMC/well, and stimulated with irra-
diated (45 Gy) donor or third-party spleen cells (5 ¥ 104 cells/well)
in 200 ml culture medium. Additionally, 24 wells contained stimu-
lator cells alone.
After 3 days of culture, 100 ml of the supernatant fluid were
harvested and transferred to U-bottomed 96-well plates (Nunc).
These plates were stored at –20°C until use in a bio-assay to
measure IL-2 production, using the IL-2-dependent CTLL-2 cell
line, and to determine the HTLpf as described below.
The remaining cells were refreshed with 100 ml culture medium
containing recombinant IL-2 (20 U/well, 12·2 ng/ml IL-2; pro-
leukin: Chiron BV, Amsterdam, The Netherlands). Each well was
individually tested for cytolytic activity against 5 ¥ 103 Europium-
diethylenetriaminepentaacetate-labelled target cells (Eu-DTPA:
Fluka, Buchs, Switzerland and Sigma, St. Louis, MO, USA). In the
case of donor stimulation, T-cell blasts of donor origin were 
used as targets and for third-party stimulation, T-cell blasts of the
third-party spleen cells were used as targets [27]. After 4 h of 
incubation at 37°C in a humidified atmosphere of 5% CO2, the
plates were centrifuged for 5 min at 600 g and 20 ml of the super-
natant fluid were transferred to 96-well plates with a low back-
ground fluorescence (fluoroimmunoplate; Nunc). Additionally,
100 ml of enhancement solution (LKB-Wallac, Turku, Finland)
were added to each well. Plates were stored in the dark at room
temperature until the fluorescence of the released Europium was
measured in a time-resolved fluorometer (Victor 1420 Multilabel
Counter, LKB-Wallac, Turku, Finland). Fluorescence was ex-
pressed in counts per second (cps). As a control for every target
cell, spontaneous lysis (target cells + culture medium) and
maximum lysis (target cells +1% Triton X-100) was determined.
Helper T-lymphocyte precursor frequency (HTLpf)
To determine the HTLpf, the concentration of IL-2 was deter-
mined in the culture supernatant fluid using the IL-2-dependent
murine CTLL-2 cell line, which is sensitive for human IL-2 and
not for human IL-4 [28].
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The HTLpf was determined as described before [27]. Briefly,
the LDA-culture supernatant fluid was thawed, the CTLL-2 cells
were extensively washed and resuspended at a concentration of 
5 ¥ 104 cells/ml. Subsequently, the CTLL-2 cells were added to 
100 ml serially-diluted recombinant IL-2 (Chiron; 100–0·05 U/ml)
or sample supernatant fluid. After 24 h of incubation, with the
final 4 h in the presence of 0·5 mCi/well 3H-thymidine, the cells were
harvested and the counts per minute (cpm) were determined.
Statistical analysis
The mean cps (CTLpf) and cpm (HTLpf) with their standard
deviation (s.d.) of the wells, in which only stimulator cells were
present, were considered as background. Experimental wells were
scored positive if the counts in that well exceeded the mean +(3
¥ s.d.) of the wells in which only stimulator cells were present. For
each cell concentration, the number of negative wells was deter-
mined and used to calculate the frequency with a computer
program designed by Strijbosch et al. [29].
The CTLpf and HTLpf (expressed as the number of CTLp or
HTLp per 106 cells) and the 95% confidence interval (CI) were
calculated by the Jackknife procedure for maximal likelihood
[29]. The calculated frequencies were accepted when the 
goodness-of-fit did not exceed 12.
The donor-specific response was expressed as the relative
response (RR), and calculated by the ratio of the donor reactiv-
ity to the third-party reactivity to correct for non-specific changes
in T-cell reactivity.
The paired Wilcoxon signed rank test was used to test the 
difference between no, high and low dose immunosuppression.
Two-sided P-values £0·05 were considered significant.
RESULTS
Donor-specific MLC
Neither the donor nor the third-party reactive MLC changed after
transplantation when analysed in no versus high, or high versus
low dose immunosuppression: median and range donor MLC (SI)
97 (1–327) versus 21 (1–852); P = 0·87, or 21 (1–852) versus 80·5
(1–964), P = 0·87, respectively; third-party MLC (SI) 176 (17–491)
versus 146 (4–2187), P = 0·89, or 146 (4–2187) versus 288 (8–1031),
P = 0·13, respectively.
The donor-specific MLC, calculated by the MLC-RR, had
decreased significantly 1 year after transplantation compared with
pre-transplantation (Fig. 1: no immunosuppression versus high
dose immunosuppression: P = 0·04). Two years after transplanta-
tion, when the immunosuppressive therapy was tapered, the
MLC-RR had not changed (P = 0·92). No significant increase or
decrease in MLC-RR compared with the reactivity under CsA
treatment was found between patients who were treated with low
dose AZA and those on low dose MMF (P = 0·78; Table 1).
Tetanus toxoid (TET) reactivity
TET reactivity did not change after transplantation under high
dose immunosuppression compared with pre-transplantation (no
immunosuppression) (P = 0·86) (Fig. 2). In contrast, when the
immunosuppressive dose was tapered, TET reactivity increased
significantly (Fig. 2: high versus low dose immunosuppression: 
P = 0·0005). No difference was found between the patients con-
verted to low dose AZA and low dose MMF (P = 0·91; Table 1).
Table 1. Change in T-cell reactivity (MLC-RR, TET, HTLp-RR, and CTLp-RR) in PBMC after
conversion from CsA to low dose azathioprine (AZA) or mycophenolate mofetil (MMF) compared 
with treatment with CsA
MLC-RR TET HTLp-RR CTLp-RR
AZA Median 0·005 26 –0·046 –0·007
Range –1·209–0·586 0–430 –0·271–10·000 –0·253–0·094
MMF Median –0·021 45·5 0·178 0·106
Range –1·260–1·705 –25–580 –2·313–0·231 –0·066–3·105
P-value 0·78 0·91 0·16 0·19
No High dose Low dose
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Fig. 1. Relative response (RR: donor/3rd-party reactivity) in MLC of 20
kidney transplant patients measured before transplantation (no immuno-
suppression), during treatment with high dose immunosuppression (1 year
after transplantation: CsA treatment (trough level: ±150 ng/ml) and Pred
(10 mg/day)), and during treatment with low dose immunosuppression 
(2 years after transplantation: 1 mg/kg/day AZA or 1 g/day MMF and 
Pred (10 mg/day)). No cells were available from one patient before 
transplantation and from one patient during treatment with low dose
immunosuppression.
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Helper T-lymphocyte precursor frequency (HTLpf)
The donor and third-party reactive HTLpf were comparable
before and after transplantation, when analysed in no versus high,
or high versus low dose immunosuppression: median and range
donor HTLpf (#/106 PBMC) 96·5 (0–548) versus 23·5 (0–528), P
= 0·11, or 23·5 (0–528) versus 29 (0–481), P = 0·50, respectively;
median and range third-party HTLpf (#/106 PBMC) 187·5 (9–804)
versus 103 (2–476), P = 0·47, or 103 (2–476) versus 222 (2–806), 
P = 0·04, respectively.
The donor-specific HTLpf calculated by the HTLp-RR was
lower after transplantation when high doses of immunosuppres-
sion were administered than before transplantation (no immuno-
suppression) (Fig. 3: P = 0·04). However, the HTLp-RR remained
unchanged when the immunosuppressive dose was tapered 
(P = 0·13). Consequently, a significant difference was still found
between no immunosuppression and low dose immunosuppres-
sion (P = 0·02). We found no difference in HTLp-RR compared
with the reactivity under CsA treatment between low AZA and
low MMF treatment (P = 0·16; Table 1).
Cytotoxic T-lymphocyte precursor frequency (CTLpf)
Neither donor nor third-party reactive CTLpf changed after
transplantation, when analysed in no versus high, or high versus
low dose immunosuppression: median and range donor CTLpf
(#/106 PBMC) 19 (0–131) versus 9 (0–172), P = 0·33, or 9 (0–172)
versus 13 (0–115), P = 0·93, respectively; third-party CTLpf (#/106
PBMC) 122 (4–294) versus 89 (19–221), P = 0·39, or 89 (19–221)
versus 91 (3–520), P = 0·21, respectively.
When patients were not treated with immunosuppression
(before transplantation) and subsequently, with high doses of
immunosuppression (after transplantation), the donor-specific
CTLpf calculated by the CTLp-RR slightly decreased (Fig. 4: 
P = 0·09). Tapering the dose of immunosuppression did not influ-
ence the CTLp-RR (P = 0·33). The change in CTLp-RR was com-
parable between the patients converted to low dose AZA and
those converted to low dose MMF (P = 0·19; Table 1).
DISCUSSION
After clinical transplantation, life-long immunosuppression is
necessary. As minimizing immunosuppression is presumed to be
beneficial, clinical trials were performed using conversion studies
from CsA to AZA or MMF, avoiding or tapering one of the
immunosuppressive drugs [6–10,12,13,30].
At present, it is not known whether T-cell reactivity will
change after kidney transplantation and after subsequent routine
tapering of immunosuppression. Therefore, we studied T-cell
reactivity in patients who were converted from CsA to AZA or
MMF, followed by successful AZA and MMF dose reduction. We
measured T-cell reactivity before transplantation (no immuno-
suppression), during high dose immunosuppression (1 year after
transplantation and treatment with CsA) and during low dose
immunosuppression (2 years after transplantation: tapered AZA
or MMF treatment). We showed that during high dose immuno-
suppression, donor-specific MLC-RR, HTLp-RR and CTLp-RR
decreased, and TET-reactivity remained unchanged, compared
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Fig. 2. Proliferative capacity (stimulation index (SI) = ratio of counts per
minute (cpm) obtained in the presence of antigen, to the cpm in the
absence of antigen) to tetanus toxoid (TET) of 20 kidney transplant
patients measured before transplantation (no immunosuppression),
during treatment with high dose immunosuppression (1 year after trans-
plantation: CsA treatment (trough level: ±150 ng/ml) and Pred 
(10 mg/day)), and during treatment with low dose immunosuppression 
(2 years after transplantation: 1 mg/kg/day AZA or 1 g/day MMF and 
Pred (10 mg/day)). No cells were available from one patient before 
transplantation.
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Fig. 3. Relative response (RR: donor/3rd-party reactivity) in HTLp of 20
kidney transplant measured before transplantation (no immunosuppres-
sion), during treatment with high dose immunosuppression (1 year after
transplantation: CsA treatment (trough level: ±150 ng/ml) and Pred 
(10 mg/day)), and during treatment with low dose immunosuppression 
(2 years after transplantation: 1 mg/kg/day AZA or 1 g/day MMF and 
Pred (10 mg/day)). No cells were available from two patients before 
transplantation and from two patients during treatment with low dose
immunosuppression.
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with the responses before transplantation (no immunosuppres-
sion). After successfully tapering the dose of immunosuppression,
donor-specific MLC-RR, HTLp-RR and CTLp-RR remained
unchanged, while TET reactivity increased significantly. Thus, in
stable renal transplant recipients, donor-specific hyporeactivity is
maintained, even after tapering immunosuppression. However, in
some patients, the responses did not fit with the overall trends.
We re-analysed the patients with MLC-RR, HTLp-RR or CTLp-
RR higher than 1 (i.e. donor response is higher than third-party
response) during low dose immunosuppression until April 2001.
We observed that the transplant of the one patient with high (>1)
MLC-RR failed by chronic rejection. The three patients with high
HTLp-RR had no problems with graft function. The creatinine
levels of the two patients with high CTLp-RR slowly increased
and in their transplants, are signs of chronic rejection. We suggest
that patients with low donor-specific T-cell reactivity may be 
candidates for further reduction of their immunosuppression.
Our MLC results confirm earlier studies comparing pre- and
post-transplant MLC responses, in which 25–66% of renal trans-
plant recipients had developed donor-specific hyporeactivity 1
year after transplantation [19,31–34]. Our data on donor-specific
hyporeactive CTLp confirm earlier results obtained in patients
with well-functioning kidney or heart allografts [16,35]. Addi-
tionally, Zanker et al. [24] described 19 kidney transplant recipi-
ents of whom only a few developed reduced T-cell reactivity;
three patients developed reduced HTLpf, one patient reduced
CTLpf, and two patients reduced HTLpf and CTLpf. De Haan et
al. [23,36] found a decrease in donor-specific CTLp 1–2 years after
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Fig. 4. Relative response (RR) in CTLp of 20 kidney transplant patients
measured before transplantation (no immunosuppression), during treat-
ment with high dose immunosuppression (1 year after transplantation:
CsA treatment (trough level: ±150 ng/ml) and Pred (10 mg/day)), and
during treatment with low dose immunosuppression (2 years after trans-
plantation: 1 mg/kg/day AZA or 1 g/day MMF and Pred (10 mg/day)). No
cells were available from two patients before transplantation and from two
patients during treatment with low dose immunosuppression. The CTLpf
assay of three patients were not reliable.
liver and lung transplantation compared with before transplanta-
tion, but this decrease did not correlate with decreased HTLp.
In line with our data on tapering immunosuppression,
DeBruyne et al. [22] and Beik et al. [20] found a decrease of
HTLpf relative to pre-transplant values. After successful with-
drawal of steroids, the HTLpf remained low in three out three
heart transplant patients [22] and seven out of nine renal trans-
plant patients [20]. However, Creemers et al. [25] and Mazariegos
et al. [26] demonstrated that the MLC-reactivity increased after
discontinuation of CsA and after stopping immunosuppression,
respectively. The first study [25] did not consider rejection
episodes after discontinuation of CsA, and even suggested that
the increased MLC response could be explained by the increased
incidence of rejection following cessation of CsA; furthermore,
they did not select patients who were successfully discontinued
from CsA. The latter study [26] was performed in only two living-
related renal transplant recipients.
Patients on chronic renal replacement therapy suffer from
general immunosuppression, leading to a deficient response to 
T-cell dependent antigens, like hepatitis B, influenza and TET
vaccination [37]. Consequently, the TET reactivity found during
high dose immunosuppression is probably comparable with that
before transplantation, as was shown in our patient group. In
general, when patients are treated with low dose immunosup-
pression, the incidence of infection is lower than during treatment
with high dose immunosuppression. This was also demonstrated
by the increase of in vitro TET reactivity after tapering immuno-
suppression. In contrast to treatment with high dose immuno-
suppression, when patients will be exposed to the TET antigen in
vivo during treatment, with low dose immunosuppression the
immune system is capable of reacting. Another possible explana-
tion for the high TET reactivity is the time after transplantation
in combination with good graft function. We cannot exclude this
explanation because in this study, we did not measure a control
group of patients with stable graft function who remained on CsA
therapy during the 2 years after transplantation.
In conclusion, donor-specific hyporeactivity can be found
after transplantation and in stable renal transplant patients, even
after tapering immunosuppression, although this latter is accom-
panied by an increased reactivity to non-HLA antigens such as
TET. Consequently, tapering immunosuppression does not lead
to an increase in donor-specific reactivity.
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